Monash Institute and Takeda Partner Up for Gastrointestinal Research

Monash Institute and Takeda Partner Up for Gastrointestinal Research
shutterstock_61876537The Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University in Melbourne, Australia has established a strategic research partnership with the Osaka, Japan-based research company Takeda in order to develop new drugs for the treatment of gastroenterology conditions with unmet medical needs. The alliance is based on the belief that several gastrointestinal disorders remain improperly treated and insufficiently understood. In order to increase knowledge and offer better treatments for diseases such as irritable bowel syndrome, abdominal pain, chronic itch, severe constipation and diarrhea, investigators from both MIPS and Takeda will conduct research focused on the underlying mechanisms of action of the diseases. The ultimate goal is to develop new and innovate treatment approaches able to improve the lives of millions of patients all over the world. The three-year research program will be led by the Deputy Director of MIPS, professor Nigel Bunnett, in collaboration with the MIPS member Daniel Poole who believes that gastrointestinal diseases are causing great human suffering. “There is no cure for many gastrointestinal diseases and current treatments are either inadequate or have major side-effects. If we can understand the mechanisms that trigger these diseases we can go on to develop effectiv
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *